卵巢癌中错配修复缺陷与MSI表型、肿瘤浸润淋巴细胞增加及免疫细胞PD-L1表达相关
研究对419例卵巢癌进行MLH1、MSH2、MSH6和PMS2免疫组化评估错配修复状态,并结合临床数据分析。结果显示2.6%为MMR阴性、4.3%为MMR低表达,63.6%的MMR阴性卵巢癌为子宫内膜样亚型,MMR阴性者I或II期诊断比例显著更高(p=0.0041),且无进展生存期优于MMR正常和MMR低表达者(p=0.0046)。
要点
- 2.6%卵巢癌为MMR阴性,其中63.6%为子宫内膜样亚型。
- MMR阴性卵巢癌I或II期诊断比例显著高于MMR正常者(p=0.0041)。
- MMR阴性者无进展生存期优于MMR正常和MMR低表达者(p=0.0046)。
核心结论
- 数据提示MMR缺陷卵巢癌是一个独特的分子亚群,以早期诊断、MSI表型和肿瘤浸润淋巴细胞增加为特征,这些患者可能是抗PD-1/PD-L1治疗的良好候选者。
研究设计与样本
- 对419例卵巢癌的全切片标本进行MLH1、MSH2、MSH6和PMS2免疫组化以评估MMR状态,并结合临床数据分析MMR缺陷的临床相关性。
- 在不同MMR状态的卵巢癌中比较MSI状态(通过MSI检测)以及CD3、CD8、PD-1和PD-L1的表达(通过免疫组化)。
主要发现
- 2.6%的卵巢癌为MMR阴性,4.3%为MMR低表达,63.6%的MMR阴性卵巢癌为子宫内膜样亚型。
- MMR阴性卵巢癌在I或II期诊断的比例显著高于MMR正常卵巢癌(p=0.0041)。
- 所有检测的MMR阴性卵巢癌均观察到MSI,检测的MMR低表达卵巢癌中14.3%观察到MSI,检测的MMR正常卵巢癌中3.2%观察到MSI。
- MMR阴性卵巢癌的无进展生存期优于MMR正常和MMR低表达卵巢癌(p=0.0046)。
- 多数卵巢癌的瘤内淋巴细胞为PD-1阳性,与MMR状态无关;MMR阴性卵巢癌较MMR正常卵巢癌显示CD3+和CD8+肿瘤浸润淋巴细胞及PD-L1+瘤内免疫细胞显著增加。
临床怎么用
- 作者认为MMR缺陷卵巢癌患者可能是抗PD-1/PD-L1治疗的良好候选者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of mismatch repair (MMR) deficiency in ovarian cancer (OC) pathogenesis and its association with other clinicopathologic features, such as microsatellite instability (MSI) and expression of checkpoint proteins, remain largely elusive. METHODS: We performed Immunohistochemistry (IHC) for MLH1, MSH2, MSH6 and PMS2 on full-section slides from 419 OCs to assess the MMR status. The clinical relevance of MMR deficiency was analyzed in combination with clinical data. The MSI status (by MSI assay) and expression of CD3, CD8, PD-1 and PD-L1 (by IHC) were compared in OCs with different MMR status. RESULTS: We found that 2.6% OCs were MMR-negative, 4.3% OCs were MMR-low, and 63.6% of MMR-negative OCs were of endometrioid subtype. A significantly higher proportion of MMR-negative OCs were diagnosed at stage I or II compared to MMR-proficient OCs (p=0.0041). MSI was observed in all tested MMR-negative OCs, 14.3% of tested MMR-low OCs and 3.2% of tested MMR-proficient OCs. In addition, MMR-negative OCs had better progression free survival compared to MMR-proficient and MMR-low OCs (p=0.0046). Furthermore, the majority of OCs were PD-1-positive in intratumoral lymphocytes regardless of MMR status; while MMR-negative OCs exhibited significantly increased CD3+ and CD8+ tumor-infiltrating lymphocytes, and PD-L1+ intratumoral immune cells compared to MMR-proficient OCs. CONCLUSION: Our data suggests that MMR deficient OC is a unique molecular subgroup, characterized by early stage of diagnosis, MSI phenotype, and increased tumor-infiltrating lymphocytes. These patients may be good candidates for anti-PD-1/PD-L1 therapy.
引用
- Xiao X, Dong D, He W, et al. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. Gynecol Oncol. 2018. PMID: 29496294. doi:10.1016/j.ygyno.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。